Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Lesson Learned

<< Previous

Bullboard Posts

Next >>

Comment by RalphRalphon Feb 17, 2021 9:48pm

164 Views

Post# 32592473

RE:RE:RE:RE:RE:RE:Lesson Learned

Their cash position (including bought deal $) is not enough to fully fund Phase 3 & maintain operations/pipeline development during that stretch of years. They are going to need additional money, in the form of an upfront payment from another partnership or an additional raise down the line.

They just essentially sold 22% of the company for $35-40M. It's obviously nice that they have more cash in the bank, but it came at a relatively high cost to shareholders. Keep in mind that it's possible to point out that fact while still holding shares & believing in the future of the company.

Arbourmark wrote:
Crow, there is lots of noise on our board. I recall for months many posting management were incompetent but then we got the Nuance deal and they were geniuses, now they raised more capital and back in the dog house. It is almost comical.

Yes there is dilution, big deal! We now have cash in the bank and can do it alone, we actually have additional cash with warrants and previous raise, we can now advance other drugs to increase our valuations.

Management has eliminated much of the risk in my opinion. Many have posted here that phase 3 companies like ATE should have market cap of $600M, why didn't we have that respect. The reason is the market had concerns we could not complete phase 3, that is no longer a concern.

We are in a much stronger position now from a negotiation point of view. Yes the weak hands will fold tomorrow but will be replaced with stronger hands. I believe much of the $35M raised will be institutional, I put in an order for 50,000 more but suspect I will be lucky to get 10,000 filled. The fact the company has removed the financial risk of not being able to complete phase 3 is huge. This is setting up a beautiful story to list on Nasdaq.